Trial · NCT07902245
Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants
NCT07902245, Phase 1, Not yet recruiting, Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants. Trials, record NCT07902245. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902245
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants
- NCT number
- NCT07902245
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- Conditions
- Safety Issues
- Interventions
- RG002C0106, 0.9% sodium chloride injection
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidences of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug. | within 169 days after the administration | Incidences of adverse events (AEs) and serious adverse events (SAEs) related to the study drug |
| Secondary | maximum drug concentration (Cmax) | at designed time points within three days after the administration | Blood samples are collected to detect drug consentration for maximum drug concentration (Cmax) |
| Secondary | PD markers | within 365 days after the administration | Blood samples are collected to detect C3 complement protein level and activity for PD evaluation |
| Secondary | Incidence of anti-drug antibodies (ADAs) against RG002C0106 Injection | within 113 days after the administration | Blood samples are collected to test ADA concentration to evaluate the immunogenicity. |
| Secondary | time to maximum concentration (Tmax) | at designed time points within three days after the administration | Blood samples are collected to detect drug consentration for time to maximum concentration (Tmax) |
| Secondary | area under the concentration-time curve from time zero to 48 hours post-dose | at designed time points within three days after the administration | Blood samples are collected to detect drug consentration for area under the concentration-time curve from time zero to 48 hours post-dose |
| Secondary | elimination half-life (t1/2) | at designed time points within three days after the administration | Blood samples are collected to detect drug consentration for elimination half-life (t1/2) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902245
GET https://conductscience.org/api/trials/v1/NCT07902245/registered